Equities Analysts Issue Forecasts for Vanda Pharmaceuticals Inc.’s Q3 2018 Earnings (VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Oppenheimer Holdings decreased their Q3 2018 earnings per share estimates for Vanda Pharmaceuticals in a research report issued on Sunday. Oppenheimer Holdings analyst D. Archila now forecasts that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.01. Oppenheimer Holdings currently has a “Buy” rating and a $25.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q4 2018 earnings at $0.04 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. During the same period in the prior year, the company posted ($0.01) earnings per share. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year.
A number of other analysts have also weighed in on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Piper Jaffray Companies lifted their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, September 14th. BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Finally, ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $21.50.
Vanda Pharmaceuticals (VNDA) traded down $0.10 during trading on Tuesday, reaching $12.85. The company’s stock had a trading volume of 340,500 shares, compared to its average volume of 557,914. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $18.99.
A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after buying an additional 186,548 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Vanda Pharmaceuticals by 10.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,890,085 shares of the biopharmaceutical company’s stock worth $33,833,000 after purchasing an additional 186,526 shares during the last quarter. State Street Corp increased its position in shares of Vanda Pharmaceuticals by 2.9% during the 2nd quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock worth $26,380,000 after purchasing an additional 46,299 shares during the last quarter. FMR LLC increased its position in shares of Vanda Pharmaceuticals by 60.7% during the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after purchasing an additional 604,900 shares during the last quarter. Finally, Rothschild Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth approximately $23,491,000. 87.28% of the stock is currently owned by institutional investors and hedge funds.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.